Innovations In Clinical Neuroscience

NOV-DEC 2017

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link:

Contents of this Issue


Page 51 of 83

52 ICNS INNOVATIONS IN CLINICAL NEUROSCIENCE November-December 2017 • Volume 14 • Number 11–12 O R I G I N A L R E S E A R C H symptoms demarcating Relief post-treatment might differ during a different study phase or in an unmedicated patient group. Because of this, comparison of relative scores using IRT methods might permit better identification of the "moderately well" patients. In conclusion, a reduced symptom burden is neither necessary nor sufficient for Remission following the AWG/SWG criteria. Subjects with symptom Relief post-treatment are not the same as those who meet Remission criteria, and those who did meet Remission criteria frequently overlapped in symptom severity with those who were not considered Remitted. This does not suggest that the Remission criteria do not successfully identify a subset of patients for whom "the disease burden was substantially lessened" as originally intended; the construction of these criteria based on the diagnostic criteria rather than empirical analyses might capture elements of the diagnostic system that are clinically relevant and affect aspects of patient's well-being that are not as well addressed by general severity of symptoms. The discrepancies between these two methods—with Remission criteria focused on DSM-defined diagnostic classification and with Relief criteria focused on the general severity of symptoms as measured on the PANSS—point out the need for future empirical research to determine the advantages of each strategy. ACKNOWLEDGMENTS The authors thank the study volunteers for participating in the research studies and the clinicians and support staff for enabling patient recruitment and clinical data collection. The authors also thank Adam Savitz, Giacomo Salvadore, Larry Alphs, Dong Jing Fu, Qingqin Li, Ibrahim Turkoz, Monique Franc, Anthony Santos, Nicole Bottrel, William Cafferty, and other staff in the Neuroscience Biomarkers of Janssen Research & Development for scientific input and operational support including anonymization of clinical data. REFERENCES 1. Kay SR, Fiszbein A, Opfer LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261. 2. Andreasen NC, Carpenter Jr WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J of Psychiatry. 2005;162:441– 449. 3. Khan A, Lewis C, Lindenmayer J-P. Use of non- Parametric Item Response Theory to develop a shortened version of the Positive and Negative Syndrome Scale (PANSS). BMC Psychiatry. 2011;11:178. 4. Santor DA, Ascher-Svanum H, Lindenmayer J-P, Obenchain RL. Item response analysis of the Positive and Negative Syndrome Scale. BMC Psychiatry. 2007;7:66. 5. Levine SZ, Rabinowitz J, Rizopoulos D. Recommendations to improve the Positive and Negative Syndrome Scale (PANSS) based on item response theory. Psychiatry Res. 2011;188: 446–52. 6. Khan A, Lindenmayer J-P, Opler M, et al. A new Integrated Negative Symptom structure of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia using item response analysis. Schizophrenia Res. 2013;150:185–196. 7. Khan A, Yavorsky C, Liechti S, et al. A Rasch model to test the cross-cultural validity in the Positive and Negative Syndrome Scale (PANSS) across six geo-cultural groups. BMC Psychiatry. 2013;1:5. 8. Khan A, Lindenmayer JP, Opler M, et al. The evolution of illness phases in schizophrenia: a non-parametric item response analysis of the Positive and Negative Syndrome Scale. Schizophr Res: Cognition. 2014;1:53–89. 9. Krekels EH, Novakovic AM, Vermeulen AM, et al. Item response theory to quantify longitudinal placebo and paliperidone effects on PANSS scores in schizophrenia. CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):543-551. 10. Anderson A, Wilcox M, Savitz A, et al. Sparse factors for the positive and negative syndrome scale: Which symptoms and stage of illness? Psychiatry Res. 2015;225:283–290. 11. Anderson AE, Mansolf M, Reise SP, et al. Measuring pathology using the PANSS across diagnoses: inconsistency of the positive symptom domain across schizophrenia, schizoaffective, and bipolar disorder. Psychiatry Res. 2017;258:207–216. 12. van der Gaag M, Cuijpers A, Hoffman T, et al. The five-factor model of the Positive and Negative Syndrome Scale I: confirmatory factor analysis fails to confirm 25 published five-factor solutions. Schizophr Res. 2006;85:273–279. 13. Cai L, Yang JS, Hansen M. Generalized full- information item bifactor analysis. Psychol Methods. 2011;16:221. 14. Edelen MO, Reeve BB. Applying item response theory (IRT) modeling to questionnaire development, evaluation, and refinement. Qual Life Res. 2007;16:5–18. 15. Reise SP. The rediscovery of bifactor measurement models. Multivariate Behav Res. 2012;47:667–696. 16. Stucky BD, Thissen D, Orlando Edelen M. Using logistic approximations of marginal trace lines to develop short assessments. Applied Psychological Measurement. 2013;37:41-57. 17. Embretson SE, Reise SP. Item Response Theory for Psychologists. London, UK: Psychology Press; 2000. 18. Samejima F. Graded response model. In: Handbook of Modern Item Response Theory. van der Linden WJ, Hambleton RK (eds). New York, NY: Springer;1997:85–100. 19. Vieta E, Nuamah IF, Lim P, et al. A randomized, placebo-and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disorders. 2010;12:230–243. 20. Berwaerts J, Lane R, Nuamah IF, et al. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo- controlled study. J Affect Disord. 2011;129:252– 260. 21. Canuso CM, Schooler N, Carothers J, et al. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. J Clinical Psychopharmacol. 2010;30:487–495. 22. Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double- blind, placebo-controlled study. J Clinical Psychopharmacol. 2007;27:6–14. 23. Canuso C, Dirks B, Carothers J, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry. 2009;166: 691–701. 24. Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo- controlled study with six-month open-label

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - NOV-DEC 2017